SCHEMBL22504377

SCHEMBL22504377

CCCCCCC(CCCCCC)COC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.51
PRSS2 P07478 1/20 0.51
PRSS3 P35030 1/20 0.51
TSHR P16473 2/20 0.49
CYP3A4 P08684 1/20 0.49
ATM Q13315 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
GPR84 Q9NQS5 7/20 0.48
FFAR1 O14842 2/20 0.48
LMNA P02545 1/20 0.48
ZDHHC7 Q9NXF8 1/20 0.47
MAPT P10636 1/20 0.47
LCK P06239 1/20 0.47
PPARD Q03181 1/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47
FFAR4 Q5NUL3 1/20 0.44
ACE2 Q9BYF1 1/20 0.44
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29240283 1.00 PRSS1 (0.51) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL6383536 1.00 PRSS1 (0.51) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL20381899 0.98 TSHR (0.51) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL14716467 0.98 PRSS1 (0.50) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL14716431 0.98 PRSS1 (0.50) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL14716407 0.98 PRSS1 (0.50) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL14716299 0.96 TSHR (0.50) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL20815546 0.94 TSHR (0.47) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL7200750 0.89 TSHR (0.47) PRSS1PRSS2PRSS3TSHRCYP3A4
SCHEMBL28656958 0.88 CYP3A4 (0.53) PRSS1PRSS2PRSS3TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357133-A1 NANOMATERIALS COMPRISING CARBONATES BEAM THERAPEUTICS INC. 2023-11-09 US disclosed
US-11344555-B2 Nucleotide analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-05-31 US disclosed
US-20200316076-A1 Nucleotide Analogs THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200316076-A1 Nucleotide Analogs NUDT1, DUT, DPYD PRSS1 3432/4885PRSS2 3954/4885PRSS3 4016/4885
US-20230357133-A1 NANOMATERIALS COMPRISING CARBONATES PHOSPHO1, CA13, SGMS2 PRSS1 4105/4885PRSS2 4244/4885PRSS3 3844/4885
US-11344555-B2 Nucleotide analogs NUDT1, DUT, DPYD PRSS1 3432/4885PRSS2 3954/4885PRSS3 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.